Every Form 4 that ANAPTYSBIO INC (ANABV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ANABV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANABV filings page.
Hughes Owen reported acquisition or exercise transactions in this Form 4 filing.
ANAPTYSBIO director Owen Hughes received a grant of restricted stock units (RSUs). On May 11, 2026, he was awarded 11,250 RSUs, each representing a contingent right to receive one share of common stock for no cash payment upon settlement.
One third of these RSUs will vest on May 11, 2027, with the remaining two thirds vesting in equal annual installments, provided he continues to serve the company on each vesting date. After this grant, his reported RSU holdings from this award total 11,250 units held directly.
Murphy Christopher M. reported acquisition or exercise transactions in this Form 4 filing.
AnaptysBio, Inc. reported a compensation-related equity grant to its Chief Financial Officer, Christopher M. Murphy. On May 11, 2026, he received 25,765 restricted stock units, each representing a right to receive one share of common stock for no cash consideration.
The RSUs vest in four equal annual installments of 25% each, starting on May 11, 2027, as long as he continues providing service to the company on each vesting date. Following this grant, Murphy holds 25,765 RSUs directly.
ANAPTYSBIO, INC President and CEO Daniel Faga reported a disposition of derivative securities. He returned 11,000 employee stock options, each exercisable for one share of common stock at $31.12 per share, to the issuer. The filing notes the option was fully vested and exercisable, and this was a non-market disposition back to the company rather than an open-market trade.
ANAPTYSBIO, INC director John A. Orwin reported option adjustments tied to a corporate separation. On April 20, 2026, he received several stock option grants for 8,250, 16,510, 16,510, 10,600, and 3,311 underlying AnaptysBio common shares at exercise prices between $10.87 and $32.17 per share, while corresponding options with higher exercise prices were disposed of back to the issuer.
Footnotes explain that, under a Separation and Distribution Agreement between AnaptysBio and First Tracks, each existing option was adjusted into options for both companies, leading to these new AnaptysBio option positions. Some options are fully vested and exercisable, while others vest monthly starting February 6, 2026.
AnaptysBio director John P. Schmid reported multiple stock option adjustments tied to a corporate separation. On the reported date, he received several option grants to buy AnaptysBio common stock and simultaneously disposed of corresponding options back to the issuer.
A footnote explains that, following a pro rata distribution under a Separation and Distribution Agreement between AnaptysBio and First Tracks, each existing option was split into an option for First Tracks shares and an option for AnaptysBio shares. As a result, Schmid acquired new AnaptysBio options in amounts determined under that agreement. One referenced stock option is fully vested and exercisable, while another vests in 1/12 monthly installments starting on February 6, 2026, contingent on his continued service.
ANAPTYSBIO director Renton Hollings reported a series of stock option adjustments tied to a corporate separation. On April 20, 2026, he acquired multiple new options to buy AnaptysBio common stock and simultaneously disposed of corresponding older options back to the issuer. The footnotes explain that, following a pro rata distribution under a Separation and Distribution Agreement between AnaptysBio and First Tracks, each existing option was split into options over both companies’ shares. These are compensation and structural option changes, all held directly, and involve derivatives only rather than open-market trades in common stock.
ANAPTYSBIO, INC President and CEO Daniel Faga reported compensation-related stock option changes rather than open-market share trades. On April 20, 2026, he both acquired and disposed of multiple employee stock options covering shares of AnaptysBio common stock.
Footnotes explain that, following a pro rata distribution under a Separation and Distribution Agreement between AnaptysBio and First Tracks, each existing option was adjusted so it became an option on both companies’ shares. As a result, Faga acquired new options to buy AnaptysBio common stock at exercise prices such as $10.87, $15.53, $17.02, $22.31, and $32.17 per share, with corresponding dispositions of prior awards back to the issuer.
Several of these options are described as fully vested or vesting 25% on specific January dates with the balance vesting in equal monthly installments over 48 months, contingent on his continued service. The filing reflects grants, adjustments, and issuer-related dispositions of options, not open-market buying or selling of common stock.